Detalhe da pesquisa
1.
Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
Value Health
; 25(6): 869-886, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35667778
2.
Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
Int J Technol Assess Health Care
; 38(1): e37, 2022 Jun 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35656641
3.
Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
Int J Technol Assess Health Care
; 38(1): e79, 2022 Nov 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36321447
4.
Examining the impact of different country processes for appraising rare disease treatments: a case study analysis.
Int J Technol Assess Health Care
; 37(1): e65, 2021 May 28.
Artigo
Inglês
| MEDLINE | ID: mdl-34044899
5.
A framework for action to improve patient and public involvement in health technology assessment.
Int J Technol Assess Health Care
; 38(1): e8, 2021 Dec 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36317682
6.
Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders.
Int J Technol Assess Health Care
; : 1-10, 2020 Sep 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32878663
7.
Stories of Patient Involvement Impact in Health Technology Assessments: A Discussion Paper.
Int J Technol Assess Health Care
; 35(4): 266-272, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31337453
8.
EVALUATION OF PATIENT AND PUBLIC INVOLVEMENT INITIATIVES IN HEALTH TECHNOLOGY ASSESSMENT: A SURVEY OF INTERNATIONAL AGENCIES.
Int J Technol Assess Health Care
; 33(6): 715-723, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-29122048
9.
IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT.
Int J Technol Assess Health Care
; 31(4): 201-6, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-26646858
10.
Generating health technology assessment evidence for rare diseases.
Int J Technol Assess Health Care
; 30(4): 416-22, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25407328
11.
Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments.
Patient
; 16(1): 7-17, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36217098
12.
Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop.
Front Pharmacol
; 14: 1289365, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38283835
13.
Consideration of quality of life in the health technology assessments of rare disease treatments.
Eur J Health Econ
; 23(4): 645-669, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-34714428
14.
Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare.
Int J Environ Res Public Health
; 19(3)2022 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35162696
15.
What principles should govern the use of managed entry agreements?
Int J Technol Assess Health Care
; 27(1): 77-83, 2011 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-21262072
16.
The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Front Pharmacol
; 12: 699466, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34456724
17.
The use of nonrandomized evidence to estimate treatment effects in health technology assessment.
J Comp Eff Res
; 10(14): 1035-1043, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34279114
18.
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
Pharmacoeconomics
; 39(9): 1021-1044, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34231135
19.
Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes.
Int J Technol Assess Health Care
; 26(3): 309-16, 2010 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-20584360
20.
Patients' perspectives in health technology assessment: a route to robust evidence and fair deliberation.
Int J Technol Assess Health Care
; 26(3): 334-40, 2010 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-20584364